Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 3,489 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 3,489 shares of the stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $29.12, for a total value of $101,599.68. Following the sale, the director directly owned 737,770 shares in the company, valued at $21,483,862.40. This represents a 0.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Cyrus Harmon also recently made the following trade(s):

• On Monday, December 22nd, Cyrus Harmon sold 2,881 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.53, for a total value of $82,194.93.

Olema Pharmaceuticals Stock Down 1.5%

Shares of OLMA stock opened at $26.72 on Wednesday. Olema Pharmaceuticals, Inc. has a twelve month low of $2.86 and a twelve month high of $36.26. The stock has a market cap of $1.83 billion, a P/E ratio of -14.29 and a beta of 1.92. The stock has a 50 day moving average of $25.82 and a 200 day moving average of $13.71. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). As a group, sell-side analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. grew its holdings in shares of Olema Pharmaceuticals by 55.4% during the second quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after buying an additional 2,168 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Olema Pharmaceuticals by 602.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after acquiring an additional 5,866 shares during the last quarter. FNY Investment Advisers LLC lifted its stake in Olema Pharmaceuticals by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after purchasing an additional 5,000 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Olema Pharmaceuticals during the 3rd quarter worth approximately $53,000. Finally, American Century Companies Inc. purchased a new stake in shares of Olema Pharmaceuticals in the second quarter valued at approximately $54,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on OLMA. UBS Group started coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, January 7th. They set a “buy” rating and a $45.00 target price on the stock. Piper Sandler assumed coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Wednesday, October 8th. Oppenheimer upped their target price on Olema Pharmaceuticals from $45.00 to $48.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Finally, Citigroup lifted their price target on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Olema Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $41.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.